The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disorders like melasma and post-inflammatory hyperpigmentation, and demand for advanced treatments such as laser therapy, chemical peels, and microneedling. North America leads the market, with the U.S. expected to reach $0.93 billion by 2035. Asia-Pacific is the fastest-growing region due to rising incomes and beauty consciousness. Key players include AbbVie, L'Oréal, and Johnson & Johnson.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
